Skip to main content
Top
Published in: Inflammation 1/2015

01-02-2015

Potential Effects of Calcium Binding Protein S100A12 on Severity Evaluation and Curative Effect of Severe Acute Pancreatitis

Authors: Zhan Yinchu, Zhang Feng, Shi Yinsheng, Wu Fengqing, Zhou Xiaoyang, Li Jin, Gao Xiaofei

Published in: Inflammation | Issue 1/2015

Login to get access

Abstract

Severe acute pancreatitis is a life threatening disease with a high rate of mortality, but its treatments are still controversial. The purpose of this study is to investigate the potential effects of calcium binding protein S100A12 on severity evaluation and curative effect of severe acute pancreatitis induced by caerulein and lipopolysaccharide in mice. Intraperitoneal injection of 50 μg/kg caerulein for seven times (every interval time was an hour) and intraperitoneal injection of 10 mg/kg lipopolysaccharide for once to establish acute pancreatitis mice models. One hundred sixty specific pathogen-free imprinting control region (ICR) female mice were randomly divided into the control group (group A, normal saline), the mild group (group B, caerulein), the severe group (group C, caerulein + lipopolysaccharide), and the intervention group (group D, S100A12 recombinant antibodies + caerulein + lipopolysaccharide); each group had 40 mice. We sampled the blood at 8, 12, and 24 h after the beginning of building animal models. In each period of time, we respectively detected the serum S100A12, amylase (AMY), C-reactive protein (CRP), interleukin (IL-1β, IL-6), and tumor necrosis factor (TNF-α) levels. In addition, we observed and scored the pancreas and lungs histopathology of the mice. In each same period of time compared with group C, serum AMY, CRP, IL-1β, IL-6, TNF-α levels of group D were significantly decreased (p < 0.05). In each same period of time compared with group B and group C, serum S100A12 concentration of group D was significantly decreased (p < 0.05), and the pancreas and lungs histopathology were also much improved. These observations demonstrate that S100A12 recombinant antibodies were able to significantly reduce the severity of acute pancreatitis induced by caerulein and lipopolysaccharide in mice. Serum S100A12 may serve as a useful marker for disease severity and curative effect in mice with severe acute pancreatitis.
Literature
1.
go back to reference Sekimoto, M., T. Takada, Y. Kawarada, et al. 2006. JPN guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis. J Hepatobiliary Pancreat Surg 13: 10–24.CrossRefPubMedCentralPubMed Sekimoto, M., T. Takada, Y. Kawarada, et al. 2006. JPN guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis. J Hepatobiliary Pancreat Surg 13: 10–24.CrossRefPubMedCentralPubMed
2.
go back to reference Granger, J., and D. Remick. 2005. Acute pancreatitis: models, markers, and mediators. Shock 24(Suppl 1): 45–51.CrossRefPubMed Granger, J., and D. Remick. 2005. Acute pancreatitis: models, markers, and mediators. Shock 24(Suppl 1): 45–51.CrossRefPubMed
3.
go back to reference Mayerle, J., V. Hlouschek, and M.M. Lerch. 2005. Current management of acute pancreatitis. Nat Clin Pract Gastroenterol Hepatol 2: 473–483.CrossRefPubMed Mayerle, J., V. Hlouschek, and M.M. Lerch. 2005. Current management of acute pancreatitis. Nat Clin Pract Gastroenterol Hepatol 2: 473–483.CrossRefPubMed
4.
go back to reference Scheiber-Camoretti, R., A. Mehrotra, L. Yan, J. Raman, J.F. Beshai, and M.A. Hofmann Bowman. 2013. Elevated S100A12 and sRAGE are associated with increased length of hospitalization after non-urgent coronary artery bypass grafting surgery. Am J Cardiovasc Dis 3(2): 85–90.PubMedCentralPubMed Scheiber-Camoretti, R., A. Mehrotra, L. Yan, J. Raman, J.F. Beshai, and M.A. Hofmann Bowman. 2013. Elevated S100A12 and sRAGE are associated with increased length of hospitalization after non-urgent coronary artery bypass grafting surgery. Am J Cardiovasc Dis 3(2): 85–90.PubMedCentralPubMed
5.
go back to reference Shiotsu, Y., Y. Mori, M. Nishimura, T. Hatta, N. Imada, N. Maki, K. Iida, N. Iwamoto, E. Matsuoka, K. Tamagaki, and A. Kosaki. 2013. Prognostic utility of plasma S100A12 levels to establish a novel scoring system for predicting mortality in maintenance hemodialysis patients: a two-year prospective observational study in Japan. BMC Nephrol 16: 14–16. Shiotsu, Y., Y. Mori, M. Nishimura, T. Hatta, N. Imada, N. Maki, K. Iida, N. Iwamoto, E. Matsuoka, K. Tamagaki, and A. Kosaki. 2013. Prognostic utility of plasma S100A12 levels to establish a novel scoring system for predicting mortality in maintenance hemodialysis patients: a two-year prospective observational study in Japan. BMC Nephrol 16: 14–16.
6.
go back to reference Saito, T., Y. Hojo, Y. Ogoyama, et al. 2012. S100A12 as a marker to predict cardiovascular events in patients with chronic coronary artery disease. Circ J 76(11): 2647–2652.CrossRefPubMed Saito, T., Y. Hojo, Y. Ogoyama, et al. 2012. S100A12 as a marker to predict cardiovascular events in patients with chronic coronary artery disease. Circ J 76(11): 2647–2652.CrossRefPubMed
7.
go back to reference Shiotsu, Y., Y. Mori, M. Nishimura, et al. 2011. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol 6(4): 718–723.CrossRefPubMedCentralPubMed Shiotsu, Y., Y. Mori, M. Nishimura, et al. 2011. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol 6(4): 718–723.CrossRefPubMedCentralPubMed
8.
go back to reference Mori, Y., A. Kosaki, N. Kishimoto, et al. 2009. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephroi 29(1): 18–24.CrossRef Mori, Y., A. Kosaki, N. Kishimoto, et al. 2009. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephroi 29(1): 18–24.CrossRef
9.
go back to reference Manolakis, A.C., A.N. Kapsoritakis, P. Georgoulias, et al. 2010. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome. BMC Gastroenterol 10: 118.CrossRefPubMedCentralPubMed Manolakis, A.C., A.N. Kapsoritakis, P. Georgoulias, et al. 2010. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome. BMC Gastroenterol 10: 118.CrossRefPubMedCentralPubMed
10.
go back to reference Foell, D., T. Kucharzik, M. Kraft, et al. 2003. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52(6): 847–853.CrossRefPubMedCentralPubMed Foell, D., T. Kucharzik, M. Kraft, et al. 2003. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52(6): 847–853.CrossRefPubMedCentralPubMed
11.
go back to reference Leach, S.T., Z. Yang, I. Messina, et al. 2007. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol 42(11): 1321–1331.CrossRefPubMed Leach, S.T., Z. Yang, I. Messina, et al. 2007. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol 42(11): 1321–1331.CrossRefPubMed
12.
go back to reference Kaiser, T., J. Langhorst, H. Wittkowski, et al. 2007. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 56(12): 1706–1713.CrossRefPubMedCentralPubMed Kaiser, T., J. Langhorst, H. Wittkowski, et al. 2007. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 56(12): 1706–1713.CrossRefPubMedCentralPubMed
13.
go back to reference Lorenz, E., M.S. Muhlebach, P.A. Tessier, et al. 2008. Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. Respir Med 102(4): 567–573.CrossRefPubMedCentralPubMed Lorenz, E., M.S. Muhlebach, P.A. Tessier, et al. 2008. Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. Respir Med 102(4): 567–573.CrossRefPubMedCentralPubMed
14.
go back to reference Foell, D., S. Seeliger, T. Vogl, H.G. Koch, H. Maschek, E. Harms, C. Sorg, and J. Roth. 2003. Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax 58(7): 613–617.CrossRefPubMedCentralPubMed Foell, D., S. Seeliger, T. Vogl, H.G. Koch, H. Maschek, E. Harms, C. Sorg, and J. Roth. 2003. Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax 58(7): 613–617.CrossRefPubMedCentralPubMed
15.
go back to reference Wittkowski, H., A. Stumock, M.A. van Zoelen, et al. 2007. Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit Care Med 35(5): 1369–1375.CrossRefPubMed Wittkowski, H., A. Stumock, M.A. van Zoelen, et al. 2007. Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit Care Med 35(5): 1369–1375.CrossRefPubMed
16.
go back to reference Shepherd, C.E., J. Goyette, V. Utter, et al. 2006. Inflammatory S100A9 and S100A12 proteins in Alzheimer’s disease. Neurobiol Aging 27(11): 1554–1563.CrossRefPubMed Shepherd, C.E., J. Goyette, V. Utter, et al. 2006. Inflammatory S100A9 and S100A12 proteins in Alzheimer’s disease. Neurobiol Aging 27(11): 1554–1563.CrossRefPubMed
17.
go back to reference Komatsuda, A., H. Ohtani, H. Wakui, et al. 2006. Increased serum levels of S100A12 in patients with MPO-ANCA-associated glomerulonephritis. Clinical Nephrology 66(5): 315–321.CrossRefPubMed Komatsuda, A., H. Ohtani, H. Wakui, et al. 2006. Increased serum levels of S100A12 in patients with MPO-ANCA-associated glomerulonephritis. Clinical Nephrology 66(5): 315–321.CrossRefPubMed
18.
go back to reference Kosaki, A., T. Hasegawa, T. Kimura, et al. 2004. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. Journal of Clinical Endocrinology Metabolism 89(11): 5423–5428.CrossRefPubMed Kosaki, A., T. Hasegawa, T. Kimura, et al. 2004. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. Journal of Clinical Endocrinology Metabolism 89(11): 5423–5428.CrossRefPubMed
19.
go back to reference Liao, H., J. Wu, E. Kuhn, et al. 2004. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheumatism 50(12): 3792–3803.CrossRefPubMed Liao, H., J. Wu, E. Kuhn, et al. 2004. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheumatism 50(12): 3792–3803.CrossRefPubMed
20.
go back to reference Foell, D., D. Kane, B. Bresnihan, et al. 2003. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 42(11): 1383–1389.CrossRef Foell, D., D. Kane, B. Bresnihan, et al. 2003. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 42(11): 1383–1389.CrossRef
21.
go back to reference Foell, D., H. Wittkowski, I. Hammerschmidt, et al. 2004. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheumatism 50(4): 1286–1295.CrossRefPubMed Foell, D., H. Wittkowski, I. Hammerschmidt, et al. 2004. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheumatism 50(4): 1286–1295.CrossRefPubMed
22.
go back to reference Ye, F., D. Foell, K. Hirono, et al. 2004. Neutrophil-derived S100A12 is profoundly upregulated in the early stage of acute Kawasaki disease. American Journal of Cardiology 94(6): 840–844.CrossRefPubMed Ye, F., D. Foell, K. Hirono, et al. 2004. Neutrophil-derived S100A12 is profoundly upregulated in the early stage of acute Kawasaki disease. American Journal of Cardiology 94(6): 840–844.CrossRefPubMed
23.
go back to reference Foell, D., F. Ichida, T. Vogl, et al. 2003. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet 361(9365): 1270–1272.CrossRefPubMed Foell, D., F. Ichida, T. Vogl, et al. 2003. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet 361(9365): 1270–1272.CrossRefPubMed
24.
go back to reference Guignard, F., J. Mauel, and M. Markert. 1995. Identification and characterization of a novel human neutrophil protein related to the S100 family. Biochem Journal 309(Pt 2): 395–401. Guignard, F., J. Mauel, and M. Markert. 1995. Identification and characterization of a novel human neutrophil protein related to the S100 family. Biochem Journal 309(Pt 2): 395–401.
25.
go back to reference Pietzsch, J., and S. Hoppmann. 2009. Human S100A12: a novel key player in inflammation? Amino Acids 36(3): 381–389.CrossRefPubMed Pietzsch, J., and S. Hoppmann. 2009. Human S100A12: a novel key player in inflammation? Amino Acids 36(3): 381–389.CrossRefPubMed
26.
go back to reference Schmidt, J., D.W. Rattner, K. Lewandrowski, C.C. Compton, U. Mandavilli, W.T. Knoefel, and A.L. Warshaw. 1992. A better model of acute pancreatitis for evaluating therapy. Annalytical Surgery 215(1): 44–56.CrossRef Schmidt, J., D.W. Rattner, K. Lewandrowski, C.C. Compton, U. Mandavilli, W.T. Knoefel, and A.L. Warshaw. 1992. A better model of acute pancreatitis for evaluating therapy. Annalytical Surgery 215(1): 44–56.CrossRef
27.
go back to reference Schmidt, J., K. Lewandrowski, C. Fernandez-del Castillo, U. Mandavilli, C.C. Compton, A.L. Warshaw, and D.W. Rattner. 1992. Histopathologic correlates of serum amylase activity in acute experimental pancreatitis. Dig Dis Sci 37(9): 1426–1433.CrossRefPubMed Schmidt, J., K. Lewandrowski, C. Fernandez-del Castillo, U. Mandavilli, C.C. Compton, A.L. Warshaw, and D.W. Rattner. 1992. Histopathologic correlates of serum amylase activity in acute experimental pancreatitis. Dig Dis Sci 37(9): 1426–1433.CrossRefPubMed
28.
go back to reference Sandler, R.S., J.E. Everhart, M. Donowitz, et al. 2002. The burden of selected digestive diseases in the United States. Gastroenterology 122: 1500–1511.CrossRefPubMed Sandler, R.S., J.E. Everhart, M. Donowitz, et al. 2002. The burden of selected digestive diseases in the United States. Gastroenterology 122: 1500–1511.CrossRefPubMed
29.
go back to reference Christophe, R., C. Laurence, K. Scott, et al. 2002. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Research 62: 1868–1875. Christophe, R., C. Laurence, K. Scott, et al. 2002. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Research 62: 1868–1875.
30.
go back to reference Rouleau, P., K. Vandal, C. Rvckman, et al. 2003. The calcium-binding protein S100A12 induces neutrophil adhesion, migration, and release from bone marrow in mouse at concentrations similar to those found in human inflammatory arthritis. Clinical Immunology 107(1): 46–54.CrossRefPubMed Rouleau, P., K. Vandal, C. Rvckman, et al. 2003. The calcium-binding protein S100A12 induces neutrophil adhesion, migration, and release from bone marrow in mouse at concentrations similar to those found in human inflammatory arthritis. Clinical Immunology 107(1): 46–54.CrossRefPubMed
31.
go back to reference Mikkelsen, S.E., V. Novitskaya, M. Kriajevska, et al. 2001. S100A12 protein is a strong inducer of neurite outgrowth from primary hippocampal neurons. J Neuro 79(4): 767–776. Mikkelsen, S.E., V. Novitskaya, M. Kriajevska, et al. 2001. S100A12 protein is a strong inducer of neurite outgrowth from primary hippocampal neurons. J Neuro 79(4): 767–776.
32.
go back to reference Gottsch, J.D., S.W. Eisinger, and S.H. Liu. 1999. Calgranulin C has filariacidal and filariastatic activity. Infect Immun 67(12): 6631–6636.PubMedCentralPubMed Gottsch, J.D., S.W. Eisinger, and S.H. Liu. 1999. Calgranulin C has filariacidal and filariastatic activity. Infect Immun 67(12): 6631–6636.PubMedCentralPubMed
33.
34.
go back to reference Sandoval, D., A. Gukovskaya, P. Reavey, et al. 1996. The role of neutrophils and platelet-activating factor in mediating experimental pancreatitis. Gastroenterology 111: 1081–1091.CrossRefPubMed Sandoval, D., A. Gukovskaya, P. Reavey, et al. 1996. The role of neutrophils and platelet-activating factor in mediating experimental pancreatitis. Gastroenterology 111: 1081–1091.CrossRefPubMed
Metadata
Title
Potential Effects of Calcium Binding Protein S100A12 on Severity Evaluation and Curative Effect of Severe Acute Pancreatitis
Authors
Zhan Yinchu
Zhang Feng
Shi Yinsheng
Wu Fengqing
Zhou Xiaoyang
Li Jin
Gao Xiaofei
Publication date
01-02-2015
Publisher
Springer US
Published in
Inflammation / Issue 1/2015
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-0032-x

Other articles of this Issue 1/2015

Inflammation 1/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.